SynAct Pharma announced this morning that the last patient has completed dosing in the phase IIb ADVANCE study, the company's pivotal trial of resomelagon (AP1189) in newly diagnosed rheumatoid arthritis. With dosing now closed across more than 30 sites, attention shifts to the topline readout, which the company continues to expect in June 2026.
Read the full article at biostock.se:
SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/